Close Menu

NEW YORK (GenomeWeb News) – Cellectricon and Fluxion Biosciences announced today they have settled a legal dispute dating back to 2009 in which Fluxion was accused of patent infringement.

Under the terms of the settlement, the firms will cross-license patents related to microfluidic cellular analysis.

Cellectricon and Fluxion said they will ask the US District Court for the Northern District of California to dismiss all claims that Cellectricon brought against Fluxion involving US Patent Nos. 7,390,650; 7,470,518; and 7,563,614.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.